Peter Tombros

Mr. Tombros’ professional career includes 8 years as President and CEO of Enzon Pharma, where he built Enzon's market capitalization from $44 million to more than $3 billion, making it one of the top 20 biotech firms in the United States at the time. Prior to that, Peter spent over 25 years with Pfizer Inc., where he helped the company to focus on and build the pharmaceutical business in a variety of positions including Vice President of Marketing; Senior Vice President, General Manager; Executive Vice President of Pfizer Pharmaceuticals; and Corporate Vice President for Strategic Planning. Mr. Tombros is currently serving an emeritus role as Professor and Distinguished Executive in Residence in the Eberly College of Sciences BS/MBA Program at the Pennsylvania State University.

Peter has also served on eight different public company boards, including NPS Pharmaceuticals, where he was Non-Executive Chairman of the Board, Cambrex, Inc., where he was Chairman of the Audit Committee, and Dendrite International, Inc. He was also a Director and Non-Executive Chairman of the Board for Alphapharma, Inc. and Pharmanet Development Group Inc. During his tenure on these boards, Peter chaired many standing board committees and has been involved in a wide variety of board matters including CEO succession, corporate restructuring, financing, regulatory (FDA, SEC) dealings, and corporate governance issues. In 2015, Mr. Tombros was selected as Director of the Year by the Financial Times. Peter was also Chairman of the 7.5-year Pennsylvania State University $2.2B Capital Campaign.

Mr. Tombros received his BS and MS at Penn State and MBA from University of Pennsylvania Wharton School of Business.